Small molecule for the treatment of malignancies and immune disorders


More than 23.5 million Americans (>7% of the population) are the existing or emerging consumers of drugs targeting autoimmune diseases alone not including immune-dependent malignancies, and the prevalence is rising. The global autoimmune disease therapeutics market size alone can exceed $125 billion by the year 2025. Similarly, immune dependent cancer market size can exceed $130 by 2030. Interleukin receptor-associated kinase 4 (IRAK4) orchestrates many chronic inflammatory diseases and high-risk solid and hematopoietic malignancies and is the prime target of pharmaceutical industries currently to develop high-commercial value new drug products. 

Technology Overview

Rochester researchers have developed a novel, selective and very-target specific IRAK4 inhibitor, which 1) Inhibits IRAK4 and it is specific to IRAK4 only; 2) has minimum off-target effects; 3) can be used in oral therapy and 4) has a short path of synthesis and no optical isomer challenges (unlike Pfizer’s PF0665833).


Targeting IRAK4 via this inhibitor can:

  • Enhance therapy for hematologic malignancies by targeting a cell-autonomous cancer cell dependency;
  • Improve marrow function via targeting the bone marrow microenvironment;
  • Block solid tumor microenvironment supported malignancies;
  • Be used in oral therapy;
  • Can potentially become a therapeutic agent for chemoresistant cancers. 


  • Immune disorders 
    • Rheumatoid arthritis
    • Lupus
    • Type-1 diabetes
    • Multiple sclerosis
  • Malignancies
    • Pancreatic cancer
    • Colitis induced tumorigenesis
    • Hematologic malignancies and chemoresistance in colorectal cancer
URV Reference Number: 6-20091
Patent Information:
For Information, Contact:
Blaze Pharoah
Licensing Manager
University of Rochester
Rakesh Singh
Richard Moore
Laura Calvi
Michael Becker